-
公开(公告)号：US10463029B1
公开(公告)日：2019-11-05
申请号：US16002233
申请日：2018-06-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Claudia Gonzaga-Jauregui , Chia-Jen Siao , Harikiran Nistala , Kalyan C. Nannuru
IPC: A01K67/027 , A61K49/00 , C07K14/78
Abstract: This disclosure relates to a rodent model of Steel Syndrome. Disclosed herein are genetically modified rodent animals that carry a mutation in an endogenous rodent Col27a1 gene, equivalent to a mutation in humans causing Steel Syndrome.
-
公开(公告)号：US20170079250A1
公开(公告)日：2017-03-23
申请号：US15268452
申请日：2016-09-16
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jennifer Schmahl , David Frendewey , Junko Kuno , Chia-Jen Siao , Gustavo Droguett , Yu Bai , Wojtek Auerbach
IPC: A01K67/027 , C12N5/0735 , G01N33/50 , C12Q1/68
CPC classification number: A01K67/0271 , A01K2207/12 , A01K2207/35 , A01K2227/105 , A01K2267/02 , C12N5/0606 , C12Q1/6876 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/5073
Abstract: Methods and compositions are provided for generating F0 fertile XY female animals. The methods and compositions involve making XY pluripotent or totipotent animal cells, in vitro cell cultures, or embryos that are capable of producing a fertile female XY animal in an F0 generation. Such cells, embryos, and animals can be made by silencing a region of the Y chromosome. Optionally, the cells can also be cultured in feminizing medium such as a low-osmolality medium and/or can be modified to decrease the level and/or activity of an Sry protein. Methods and compositions are also provided for silencing a region of the Y chromosome in an XY pluripotent or totipotent animal cell, or in vitro cell cultures, embryos, or animals derived therefrom, by maintaining an XY pluripotent or totipotent animal cell in a feminizing medium. Methods and compositions are also provided for maintaining a population of XY pluripotent or totipotent animal cells in a feminizing medium and selecting cells or clones having increased capabilities for producing a fertile female XY animal in an F0 generation. Methods and compositions are also provided for screening for compounds with feminizing activity or for optimizing concentrations of components in feminizing media.
-
公开(公告)号：US11499164B2
公开(公告)日：2022-11-15
申请号：US17245437
申请日：2021-04-30
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Susannah Brydges , Jose F. Rojas , Gregg S. Warshaw , Chia-Jen Siao
Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.
-
公开(公告)号：US11111504B2
公开(公告)日：2021-09-07
申请号：US16838621
申请日：2020-04-02
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Susannah Brydges , Jose F. Rojas , Gregg S. Warshaw , Chia-Jen Siao
Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.
-
公开(公告)号：US20200318134A1
公开(公告)日：2020-10-08
申请号：US16838621
申请日：2020-04-02
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Susannah Brydges , Jose F. Rojas , Gregg S. Warshaw , Chia-Jen Siao
Abstract: Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.
-
Patent Agency Ranking
公开(公告)号：US11622547B2
公开(公告)日：2023-04-11
申请号：US16894302
申请日：2020-06-05
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Qing Fang , Chia-Jen Siao , Dan Chalothorn , KehDih Lai , Leah Sabin , Rachel Sattler , Brian Zambrowicz , Lori Morton
IPC: A01K67/027 , A61K49/00 , C07K14/76 , C12N15/85
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.
-
公开(公告)号：US10412939B2
公开(公告)日：2019-09-17
申请号：US15254016
申请日：2016-09-01
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Chia-Jen Siao , Hoi-Ching Lee , Zhe Li , Ka-Man Venus Lai , Gavin Thurston
IPC: A01K67/027 , C12N5/0735 , C07K7/08 , C12N15/85
Abstract: This disclosure provides a rodent model of prostate cancer. The rodents disclosed herein comprise a transgene that provides prostate-specific expression of an oncogenic protein (e.g, an SV40 tumor antigen) under the control of 5′ and 3′ regulatory regions of a mouse probasin gene. The rodents develop progressive forms of prostate tumor that resemble the development of human prostate cancer.
-
公开(公告)号：US20170055505A1
公开(公告)日：2017-03-02
申请号：US15254016
申请日：2016-09-01
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Chia-Jen Siao , Hoi-Ching Lee , Zhe Li , Ka-Man Venus Lai , Gavin Thurston
IPC: A01K67/027 , C07K7/08 , C12N5/0735
CPC classification number: A01K67/0275 , A01K67/0271 , A01K2207/12 , A01K2217/05 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A01K2267/0393 , C07K7/08 , C07K2319/50 , C07K2319/61 , C12N5/0606 , C12N2015/8572 , C12N2830/008 , C12N2830/36
Abstract: This disclosure provides a rodent model of prostate cancer. The rodents disclosed herein comprise a transgene that provides prostate-specific expression of an oncogenic protein (e.g, an SV40 tumor antigen) under the control of 5′ and 3′ regulatory regions of a mouse probasin gene. The rodents develop progressive forms of prostate tumor that resemble the development of human prostate cancer.
Abstract translation: 本公开提供了前列腺癌的啮齿动物模型。 本文公开的啮齿动物包含在小鼠probasin基因的5'和3'调节区的控制下提供致癌蛋白（例如，SV40肿瘤抗原）的前列腺特异性表达的转基因。 啮齿动物形成类似前列腺癌发展的前列腺肿瘤的进展形式。
-
公开(公告)号：US20230337645A1
公开(公告)日：2023-10-26
申请号：US18316409
申请日：2023-05-12
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Daisuke Kajimura , Aarti Sharma-Kanning , Brittany Dubose , Gustavo Droguett , Chia-Jen Siao , Junko Kuno , David Frendewey , Brian Zambrowicz
IPC: C12N15/90 , C12N15/85 , A01K67/027 , C12N9/22
CPC classification number: A01K67/0276 , C12N9/22 , C12N15/85 , C12N15/90 , A01K2217/075 , A01K2227/105
Abstract: Nuclease-mediated methods for expanding repeats already present at a genomic locus are provided. Non-human animal genomes, non-human animal cells, and non-human animals comprising a heterologous hexanucleotide repeat expansion sequence inserted at an endogenous C9orf72 locus and methods of making such non-human animal cells and non-human animals through nuclease-mediated repeat expansion are also provided. Methods of using the non-human animal cells or non-human animals to identify therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative disorders associated with repeat expansion at the C9orf72 locus are also provided.
-
公开(公告)号：US20230232797A1
公开(公告)日：2023-07-27
申请号：US18175010
申请日：2023-02-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Qing Fang , Chia-Jen Siao , Dan Chalothorn , KehDih Lai , Leah Sabin , Rachel Sattler , Brian Zambrowicz , Lori Morton
IPC: A01K67/027 , A61K49/00 , C07K14/76 , C12N15/85
CPC classification number: A01K67/0278 , A61K49/0008 , C07K14/76 , C12N15/8509 , A01K2207/15 , A01K2227/105 , A01K2267/03 , C12N2015/8527
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.017 seconds)
